A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production

This study has been completed.
Sponsor:
Information provided by:
Harbor Therapeutics
ClinicalTrials.gov Identifier:
NCT00991107
First received: October 5, 2009
Last updated: March 8, 2011
Last verified: March 2011

October 5, 2009
March 8, 2011
September 2009
August 2010   (final data collection date for primary outcome measure)
Safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects [ Time Frame: Study duration and 1-month follow-up ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00991107 on ClinicalTrials.gov Archive Site
Activity of HE3286 on insulin sensitivity and hepatic glucose production in obese insulin-resistant adult subjects. [ Time Frame: Study period (28-days) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production
A Phase I, Open Label Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production When Administered Orally to Obese Insulin-Resistant Adult Subjects for 28 Days

The objectives of this study are to evaluate the safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects and, to assess the activity of HE3286 on insulin sensitivity and hepatic glucose production in obese insulin-resistant adult subjects.

Hollis-Eden Pharmaceuticals, Inc. is developing a new class of therapeutics for the treatment of Type 2 diabetes mellitus (T2DM). The investigational drug, HE3286, is a synthetic analog of a naturally occurring hormone with a potentially new mechanism of action that may improve the current therapeutic options available to a T2DM patient.

The glucose clamp is the gold standard for measurement of insulin sensitivity. Given the observed activity of HE3286 in reducing insulin resistance in both impaired glucose intolerant subjects and type 2 diabetic patients, it is necessary to evaluate the physiological site of action (i.e. liver vs. skeletal muscle) of HE3286 in order to further understand the mechanism of action and to design future clinical trials.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Insulin Resistance
Drug: HE3286
HE3286 20 mg (10 mg BID) for 28 days
Other Name: TRIOLEX
Experimental: HE3286
HE3286 20 mg (10 mg BID)
Intervention: Drug: HE3286
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5
August 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subject 18-65 years of age
  • Body Mass Index (BMI) is at least 29 kg/m2 but no more than 35 kg/m2 for females and no more than 37 kg/m2 for males
  • Subject has fasting blood glucose level of < 126 mg/dL at Screening
  • Subject has a 2 hour postprandial (following 75 grams glucose administration) blood glucose of 140-200 mg/dL at Screening
  • Subject has fasting plasma insulin >=10 μU/mL

Exclusion Criteria:

  • Subject has a history of clinically significant cardiovascular disease (including coronary artery disease), clinically significant hepatic, respiratory or renal abnormalities, clinically significant endocrine disorders (including history of diabetes); or clinically significant neurological or psychiatric condition;
  • Subject has any clinically significant abnormalities in laboratory results at screening
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00991107
HE3286-0103
No
Dwight R. Stickney, MD - Chief Medical Officer, Hollis-Eden Pharmaceuticals
Harbor Therapeutics
Not Provided
Study Director: Dwight R. Stickney, MD Harbor Therapeutics
Harbor Therapeutics
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP